On June 8, 2021 Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, reported that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,028,166 entitled, "Albumin Domain Fusion Proteins" (Press release, Sonnet BioTherapeutics, JUN 8, 2021, View Source [SID1234583707]). The patent covers Sonnet’s Fully Human Albumin Binding (FHAB) technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention and provide extended pharmacokinetics (PK), and the patent carries a term effective until March 2039.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This intellectual property approval is an important milestone that provides significant differentiation from any existing or emerging competitive technologies that may leverage Human Serum Albumin," said Pankaj Mohan, Ph.D., Founder and CEO. "This represents the strategic foundation underpinning our product pipeline roadmap and provides important validation for our FHAB platform. Through the development of our product pipeline, we are very excited to extend our unique and patent-protected technology to patients."
Sonnet’s FHAB platform consists of a single, fully human construct of a FHAB antibody fragment that has high affinity to bind to human albumin. The platform provides an off-the-shelf lock and load opportunity to rapidly develop numerous therapeutic biologics.
John Cini, Co-Founder and CSO, commented "The FHAB platform technology endows all Sonnet pipeline assets with a mono- or bi-specific mechanism of action. When tested in vivo against numerous wild type cytokines, Sonnet’s FHAB-derived candidates have reproducibly shown improved efficacy. Based on a linear, flexible structure, FHAB displays improved penetration and retention in the TME, and enhanced payload delivery to the tumor, via both passive and active transport mechanisms, as well as extended pharmacokinetics."